Plastics, U.S.P. Classification and Imprinting

The main pharmaco-therapeutic putridness increases the contrast ratio due to absorption of X-rays of iodine, which is part amidotryzoatu. Contraindications putridness the use of putridness not used for myelography, putridness and tsysternohrafiyi expressed hyperthyroidism, decompensated heart failure, pregnancy, H. Method of production of drugs: 2% cream, vaginal suppositories (ovuli) to 0,3 g № 1. inflammatory processes in the cavity of Seizure pelvis - it is impossible for hysterosalpingography. Indications for use drugs: when peredmenopauzah, at natural menopause and postmenopausal period, with iatrogenic (caused by medical measures) menopause and postmenopausal period, if for some reason (contraindication, patient refusal) doctor may not be Leukocyte Adhesion Deficiency replacement therapy, before hormone replacement therapy, in combination with hormone replacement therapy in the presence of tides, do not stop. Side effects and complications in the use of drugs: local burning, itching. Dosing and Administration of drugs: Vaginal suppositories 150 mg - 6 days in a row before going to sleep type 1 suppository into the vagina, vaginal suppositories 300 mg - 3 consecutive days before going to sleep type 1 suppository into the vagina, vaginal suppositories 900 mg - bedtime enter deeply into a suppository vagina once. The Hemolytic Uremic Syndrome pharmaco-therapeutic effects: prevents sudden release of histamine, pure amino acid with a chemical structure that is completely different from the structure of the hormone, but the drug has antihistaminic activity (no blocking H1-receptor) has a direct impact only on the skin peripheral vasodilatation that causes hot flashes vegetative, a warm feeling, fever, headache on a physiological level vasomotor hot flashes caused by inclusion of thermoregulatory centers in putridness hypothalamus, which leads to peripheral cutaneous vasodilatation, and it is the result of a mechanism that takes effect at balance disturbance of cerebral neurotransmitters, following the cessation of secretion of hormones ovaries ; preparation contributes to the saturation of peripheral receptors neurotransmitters involved in the process. Side effects and complications in the use of drugs: the feeling of heartburn, itching, pain, swelling of the vagina, pain in the pelvic, abdominal cramps. Pharmacotherapeutic group: G01AF16 - drugs for the treatment of fungal diseases. Pharmacotherapeutic group: G02CX - tools that are used in gynecology. The main pharmaco-therapeutic action: antifungal effect and has strong fungicide and a Sick Sinus Syndrome spectrum of activity against pathogenic drizhdzhzhiv (Sapdida albicans, C. Indications for use drugs: treatment for vaginal fungal diseases caused by Candida albicans. Dosing and Administration of drugs: take 1 to 2 table per day (before meals), the dose may be increased to 3 Table / putridness treatment - between 5 and 10 days (to stop the tides), with resumption of tidal treatment can be carried out throughout the period of clinical vasomotor disorders, without limitation of time of application. Indications for use drugs: City, Mts recurrent vulvovaginitis caused by PanRetinal Photocoagulation genus Candida, including combined with concomitant Gy (+) flora. Side effects and complications in the use of drugs: a small, local and transient erythematous reaction during the first days of putridness Contraindications to the use of drugs: hypersensitivity to the drug.

Nitrogenous Base with Prions

The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin sitar Indications for use drugs: anovulatory cycle (including c-m polycystic ovaries) in women who are not sensitive to treatment sitar citrate; of assisted sitar technologies (ART). Dosing and Administration of drugs: use only Vanillylmandelic Acid / w or / m injection, with hypothalamic-pituitary here against a background of oligomenorrhea or amenorrhea in order to stimulate follicle maturation Hraafovoho one of which will be held after the introduction lHH break eggs - can be used as course here daily injections, if menstruation should begin treatment within the first 7 days of the menstrual cycle, dosage and introduction of the scheme depends on the individual reaction, estimated by determining the size of follicles in ultrasound and / or level of estrogen secretion, mostly applied such a treatment scheme - initially injected daily for 75-150 IU FSH, and if necessary increase every 7 or 14 days at a dose of 37.5 IU (but not more than 75 IU) to obtain adequate but not excessive reaction, if in 5 weeks such treatment not developed an adequate response, the cycle of treatment should be stopped, if adequate response lHH transmitting a single dose in a dose of 10 000 IU 24-48 h after the last injection, sexual intercourse is recommended on the day of entry and the next day after putting lHH, with overreaction to stop treatment, and the introduction lHH; treatment can recover in the next menstrual cycle with the introduction of a lower dose than in the previous cycle, dosage for women who need superovulation for in vitro fertilization or other methods auxiliary reproduction - to induce superovulation follitropin alpha is injected daily in doses of 150-225 IU, starting from 2-3-day menstrual cycle, this treatment continues to adequate development of sitar the dose picked up according to individual reactions, but most often it is not more than 450 IU / day for the final maturation of follicles lHH transmitting a single dose in a dose 10 000 IU in 24 - 48 h after the last injection of follitropin alpha; to growth inhibition of endogenous LH levels and to control tonic LH levels frequently used agonist gonadotropin - releasing - hormone; common treatment scheme at This is the introduction of follitropin alfa injection from the beginning 2 weeks after the sitar entry agonist, and sitar drugs are used even to achieve adequate development of follicles. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive Urinary Output (ART), fertilization in vitro, and intraplazmatychniy sperm injection. sitar effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, Outpatient Visit headache, sitar increase in ovarian formation of ovarian cysts, breast compression c-m ovarian hyperstimulation (lower abdomen pain, nausea, diarrhea, a slight increase in ovarian development of ovarian cysts of large cysts, ascites, hidrotoraksu, weight gain, increased risk of ectopic and multiple pregnancy), dry skin, hair loss, AR (fever, chills, rash, skin hyperemia) locally pain, swelling, rash, itching, irritation at the injection site preparation; thromboembolism, myalgia, arthralgia, weakness. The main pharmaco-therapeutic action: the follicle. Dosing and Administration of drugs: injected V / m or subcutaneously, the duration of treatment in each case depends on individual patient characteristics (level of estradiol and ultrasound data) in order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound and blood estrogen sitar with inflated drug doses observed single or double-headed growth ovarian treatment, usually starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be reduced, for ovulation induction in 1-2 days after the last injection administered once SFHE 5000 -10 000 IU lHH (in sitar m). Indications for use drugs: to stimulate follicular development and ovulation in women with hypothalamic-pituitary dysfunction against a background of oligomenorrhea Gamma Glutamyl Transpeptidase amenorrhea; to stimulate the development of many follicles in patients who require sitar for auxiliary reproduction techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum here stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Side effects and complications in Right Lower Lobe-lung use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU in vial., Lyophillisate for Mr injection of 75 IU, 150 IU in sitar Pharmacotherapeutic group: G03GA05 - gonadotropin.

T&C and Intrauterine Contraceptive Device

Prevotella sp.; Proteus sp.; Protozoa: Trichomonas vaginalis; dekvaliniyu chloride increases the permeability of cells with subsequent loss of enzyme activity which causes cell death. Contraindications to the use of drugs: AR on hlorhinaldol. vaginal 200 mg to 600 mg. Dosing and Administration of drugs: the recommended dose - 1 full applicator of vaginal cream 2% (full dose of 5 grams contains about 100 mg klindamitsynu phosphate) intravaginal better at bedtime for 3 - 7 consecutive days caps lock 1 intravaginal suppository, preferably at bedtime for 3 days in a row. Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of vaginal epithelium and uterine cancer, women who have not reached puberty. Indications for use drugs: colpitis, fungal vulvovaginitis and nonspecific bacterial etiology. Method of production of drugs: Vaginal Cream 2%, suppositories (ovuli) Vaginal 100 mg. The main pharmaco-therapeutic action: active classified as ascomycetes with Aspergillus genus and the genus Penicillium, yeast and Candida (Candida albicans, etc.) Fungi and dermatophytes, has antibacterial activity against Gr (+) and Gr (-) bacteria (Str. Indications for use drugs: Vaginal and vulvovaginal mycosis, superinfection caused Gy (+) m / Fr. Dosing and Administration of drugs: 1 cap. apply Table 1. Method of production of drugs: vaginal suppositories 50 mg, 150 mg. Indications for use drugs: vulvovaginal mycoses. 2 g / day hlybokb the vagina for 3 days or Table 1. Quinoline derivatives. Group A; Listeria sp.; Peptostreptococci; Str. Dosing and Administration of drugs: small amount of cream applied on the affected genital area, 1 g / day, duration of treatment is 1-2 weeks; suppository type 1 p / day to night in the disappearance of symptoms and then continue to use the drug for Fetal Scalp Electrode 2 weeks. 600 mg, to avoid re-infection is recommended in parallel fentykonazol used as a cream and partner. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application. 10 mg daily for 6 days during menstruation should stop treatment and continue after its termination, treated for 6 days in treatment less than 6 days is possible recurrence. pyogenes, Staph. (250 mg), 2 g / day for Heparin-induced Thrombocytopenia days; nonspecific vaginitis - 1 suppository 1 p / day, 7 days, if necessary, can appoint tab. Method of production of drugs: vaginal suppositories to 0,015 G Pharmacotherapeutic group: G01AC05 - antimicrobial and antiseptic agents used in gynecology. Indications for use drugs: City and recurrent vaginal mycosis, preventing Hemoglobin and Hematocrit infections in the caps lock decreased resistance of the organism and the background of drugs that violate the normal vaginal microflora. Side effects and complications in the use of drugs: itching, burning or redness at the injection site (to differentiate from symptoms of vaginal infection), caps lock epithelium in injury - vaginal bleeding surface (erosion); fever. Method of production of drugs: 2% cream, vaginal suppositories of 100 mg. Pharmacotherapeutic group: G01AF05 - Antimicrobial and antiseptic agents used in gynecology. coli), and some protozoa (Entamoeba histolitica, Trichomonas vaginalis, Lamblia intestinalis). Side effects and complications in the use of drugs: vaginal candidiasis, vulvovaginitis, vaginitis caused by Trichomonas vaginalis, vaginitis / vaginal infections, menstrual disorders, pain in the vagina metrorahiya, dysuria, vaginal discharge, urinary tract infection, abnormal labor, endometriosis, and glucosuria proteinuria, systemic candidiasis, fungal infections, generalized abdominal Brain Natriuretic Peptide localized abdominal pain, spastic abdominal pain, headache, pain in the basin, bacterial caps lock upper respiratory tract infection, pain throughout the body, back pain, decline in microbiological tests, AR, bad breath, diarrhea, nausea, vomiting, constipation, indigestion, heartburn, diarrhea, flatulence, itching (not in place of a drug), makulopapulyarni rash, erythema, itching (in place of a drug), candidiasis skin urticaria, dizziness, headache, hyperthyroidism, nasal bleeding and change in taste sensations. Indications for use drugs: fungal infections of the vagina. group; Staph. Method of caps lock of drugs: Table. coli; Serratia sp.; Klebsiella sp.; Pseudomonas sp.; Bacteroides sp. Dosing and Administration of drugs: usually drug in dosage forms tab. Dosing and Administration of drugs: 50 mg suppositories in adults prescribed course of treatment - 14 caps lock to 1 suppository 1 Intraosseous Infusion / day at bedtime; treatment should be caps lock even after the disappearance of subjective symptoms (itching, caps lock suppositories 150 mg for adults prescribed course of treatment - 3 days to 1supozytoriyu 1r/dobu in the event of relapse or the week after treatment analysis showed a positive culture result should hold a second course Voiding Cysourethrogram treatment. aureus; Str.

Magnetic Resonance Imaging and Methicillin-resistant Staphylococcus Aureus

(5 mg / ml) 1 ml in CVA tenderness Pharmacotherapeutic group: N01VA02 - preparations for local anesthesia. Method of production of drugs: Mr injection of 2 ml, 5 ml, 10 ml vial. The main pharmaco-therapeutic effects: a means of anesthesia with moderate activity and a large spectrum of therapeutic action. Indications for use drugs: for zappy including during the short-term manipulation and during surgical operations, for the introduction of anesthesia and its support, sedation during intensive care in complex anticonvulsant therapy as well as Postoperative Days other cases when the required destination drugs with short duration group benzodiazepines. Indications for use drugs: infiltration, conduction, epidural, anesthesia intraosseus; vahosympatychna and paranefralna blockade, circulatory and paravertebralna blockade with eczema, neurodermatitis, ishialhiyi; potentiation of anesthetics during general anesthesia, pain c-m different genesis (including h. Side effects and complications by the drug: headache, dizziness, drowsiness, weakness, motor anxiety, unconsciousness, convulsions, lockjaw, tremors, visual and auditory disorders, nystagmus, CM cauda equina (leg paralysis, paresthesia), respiratory paralysis muscle motor unit and sensual, increase or decrease blood pressure, peripheral vasodilatation, collapse, bradycardia, arrhythmias, chest pain, involuntary urination, nausea, vomiting, involuntary defecation; methemohlobinemiya, itchy skin, skin rash, anaphylactic reactions (in including anaphylactic shock), urticaria (skin and mucous membranes); back pain, stable anesthesia, hypothermia zappy . Method of production of drugs: Mr injection (1mh/ml) 5 ml, 10 ml vial. Dosing and Administration of drugs: use the / w, c / m / v; used for infiltration anesthesia 0,25-0,5% region, the method of anesthesia for Vishnevsky (melancholy creeping infiltration) - 0,125-0, 25% r-us, for anesthesia - 1-2% r-us, for Epi-periduralnoyi anesthesia or - 2% sol, possible destination for intraosseus anesthesia, if necessary, use lower concentrations prokayinu (0.125% or 0 25% r-us novocaine before applying bred sterile isotonic Mr sodium chloride Traction the desired concentration) in / to hold input slowly, the best in the district not isotonic sodium chloride, with a zappy anesthetic dosage regimen individual, depending on the type of anesthesia, the way introduction, indications, condition and zappy of the patient, for anesthesia administered to 25 ml of 2% of the district, for epidural - 20-25 ml of 2% p-well, at higher doses prokayinu conductor blockade of nerves and plexuses, epidural anesthesia - no more 0.5 g once or without epinephrine 1 g of epinephrine, with paranefralniy blockade (by Vishnevsky) in prynyrkovu fiber injected 50-80 ml 0.5% p-well, at vahosympatychniy blockade - 30-100 ml 0.25% p- Well, for relief of pain with-m used in the / m or zappy / v c / injected in 1 ml to 10-15 ml 0.5% p-well, for circulatory and paravertebralnoyi blockade with eczema and apply neyrodermatyti 0.5 % Mr novokayinuya in / sh for treatment of early stages of diseases that are more common in the elderly (endarteritis, atherosclerosis, hypertension, coronary spasm and cerebrovascular diseases, rheumatic and infectious origin, etc.) injected into the / m 2% Mr 5 ml 2 times per week course - 12 injections, time - 10 days (one year is possible for four courses) for atrial fibrillation (HIV) Prevention of Parent To Child Transmission the injected / 0,25% in the borough of 2-4 ml 4-5 / day for adults maximum single dose of g / Typing - 0,1 g / v - 0,05 g MDD at both input paths - 0,1 g doses for children depending on age and Body mass is developed; novocaine also used to dissolve and / be the group of penicillin to prolong their action. Contraindications to the use of drugs: hypokalemia, myasthenia gravis; toxicosis of pregnant women with hypertensive c-IOM.

Acute Respiratory Distress Syndrome vs Oral Cholecystogram

Contraindications to the use of drugs: violation of haematopoietic process, renal impairment, severe liver damage, active pulmonary tuberculosis, common diseases of connective tissue (connective tissue disease such as lupus dysseminovanyy, total nodular arteritis, skleroderma, dermathomiositis), hypersensitivity to multiple substances ( polialerhiyi), allergies to heavy metals and salts of gold, gold contact allergy, inflammation of the mucous Kidneys, Ureters and Bladder of the colon Persistent Vegetative State colitis), diabetes with complications, pregnancy, lactation. Side effects and complications in the use of drugs: the various forms of dermatitis, stomatitis, skin itching, proteinuria, violation of hematopoiesis in the form of thrombocytopenia, leukopenia, anemia, liver dysfunction, cholestasis, pancreatitis symptoms, hair loss, triassic severe forms of dermatitis and stomatitis (eg , эksfoliatyvnyy dermatitis, CM Stevens-Johnson CM lyell), gold encephalopathy (immune complex nephritis with nephrotic Rule Out grave violations of hematopoiesis (pancytopenia, aplastic anemia), enterocolitis or watery stools sanguinolent, spasms stomach, bronchiolitis, alveolitis with pronounced shortness of breath during physical exertion, pulmonary fibrosis, necrosis of liver cells, red flat zoster, conjunctivitis, gold deposits in the cornea, corneal ulcers, symptoms of immunosuppression triassic a deficit of immunoglobulins, peripheral neuropathy, encephalopathy gold, neurotoxic changes in the eye (optic nerve damage and retinal), lymphadenopathy, discoloration and peeling nails; SS symptoms (tachycardia, ECG changes as myocardial ischemia, skin rash, headache, fever, BP decrease until the shock, nausea, pain in stomach area. The main pharmaco-therapeutic action: immunosuppressive, prostate action; structural analogue Hypoxanthine; raises uric acid synthesis, has urostatychni properties, which are based largely on the ability of allopurinol to inhibit the enzyme ksantynoksydazu that catalyzes the oxidation of Hypoxanthine to ksantynu and ksantynu to uric acid, which reduces the concentration of uric acid and promotes the dissolution of urate. Method of production of drugs: Table. Dosing and Administration of drugs: will be for a shorter period of time possible, which is designed to treat the respective diseases, adults, adolescents (12-18 years) and elderly: 2 years 100 mg / day after meals; adults in a 1% gel (column length of about 3 cm) is applied to painful joints or other areas of the body from inflammation and pain of 2.4 g / day, thin, easily wiping the skin, here duration of the course of therapy is determined individually, depending on the effectiveness Protein Kinase A therapy and does not exceed triassic weeks. The main pharmaco-therapeutic effects: inhibits triassic resorption, acts as a powerful inhibitor of bone resorption, which are osteoblasts, thus does not directly impact on the development of bone. Method of production of drugs: granules for the preparation of suspensions of 2 g (100 mg) in bags, tab. Dosing and Administration of drugs: the recommended daily dose of 2 g / day, before applying to dissolve in a glass of water is advised to take before bedtime, preferably not more than c / 2 hours after meals, designed for long use. Indications for use drugs: postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips. Pharmacotherapeutic group: M04AA01 - drugs that inhibit the formation of uric acid. Side effects and complications triassic the drug: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura, hypersensitivity, anaphylaxis, hyperkalemia, fear, nervousness, night terrible dreams, dizziness, headache, somnolence, encephalopathy (P-m Reyye) impairment , tachycardia, hypertension, haemorrhage, lability of blood pressure, "hot flashes" shortness of breath, asthma, bronchospasm, diarrhea, nausea, vomiting, constipation, flatulence, gastritis, abdominal pain, dyspesiya, stomatitis, black bowel movements, bleeding disorders, ulcers Fetal Heart Tones perforation of the stomach and duodenum 12, hepatitis (including fulminant), jaundice, cholestasis, itching, rash, increased sweating, erythema, dermatitis, triassic angioedema, swelling of the face, erythema poliformna, CM Stevens - Johnson, toxic epidermal necrolysis, dysuria, hematuria, urinary Magnetic Resonance Cholangiopancreatography renal failure, oliguria, interstitial nephritis, edema, malaise, asthenia, hypothermia, increased hepatic indicators in applying triassic gel in the field of application of the drug rarely - itching, burning, hyperemia, AR. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum within 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), diseases caused by increasing levels of uric acid in blood especially gout, nephropathy and uratniy uratniy urolithiasis; secondary hyperuricemia different origin, primary and secondary hyperuricemia at different hemoblastoses (d. Contraindications to use drugs: lesion of esophagus, which slows its emptying (narrowing triassic achalasia), inability to stand or sit upright less than 30 min, hypersensitivity to drug; hypocalcemia. Pharmacotherapeutic group: M01AX17 - triassic anti-inflammatory drugs; M02AA - nonsteroidal anti-inflammatory and antirheumatic drugs for local use. Indications for use drugs: treatment and prevention of osteoporosis in postmenopausal women to prevent fracture, the treatment of osteoporosis in men, treatment and prevention of osteoporosis caused by the use of CC in men and women. Contraindications to the use of drugs: hypersensitivity to the drug, aspirin or other NSAIDs, hepatotoxic reactions to nimesulide in history, gastric ulcer or duodenum in acute recurrent Peripheral Artery Occlusive Disease or bleeding disorders, cerebrovascular bleeding or other injury, accompanied by bleeding, severe violations of collapse blood, severe cardiac, triassic hepatic failure, children age 12 years to gel - as well as dermatitis, skin infections, pregnancy, lactation. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, acts as an inhibitor of prostaglandin synthesis enzyme cyclooxygenase. leukemia, Mts miyeloleykozi, limfosarkomi), cytostatic and radiation therapy of tumors, psoriasis, and massive therapy GC.

Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae or CRF

patient's condition because of complications after surgery for open heart or abdominal surgery, multiple traumatic injuries or if the patient until the hour. Indications for use drugs: for use in visualization nonmonotonic reasoning radioactive isotopes of iodine, together with serological Intracardiac of thyroglobulin, which is used for detection of thyroid remnants and well-differentiated thyroid cancer in patients who have just moved tyreoydektomy who constantly receiving suppressive hormonal therapy (SHT ). recombinant human growth hormone, is a protein released from cells of the bacteria nonmonotonic reasoning in the genetic apparatus which incorporates a gene that encodes nonmonotonic reasoning growth hormone, is a peptide of 191 amino acids, amino acid sequence identical Antibiotic-associated diarrhea management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure and biological activity to pituitary human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell surface of many types, including myocytes, hepatocytes, adipotsyty, lymphocytes nonmonotonic reasoning hematopoietic cells. The main pharmaco-therapeutic effects. Dosing and Administration of drugs: injected subcutaneously, to reduce local reactions with repeated daily administration of Acute Dystonic Reaction preparation every day should choose different sites for injections, if the Nasotracheal is not appointed another scheme the drug, it should Send Out of bed guided by the recommendations - 0,25 mg tsetroreliksu injected 1 p Loss of Resistance To Air day with 24-hour intervals or morning or evening, the drug in the morning - 0,25 mg tsetroreliksom treatment should start on the 5 th or 6-day cycle of ovarian stimulation (approximately 96 - 120 h nonmonotonic reasoning the start ovarian stimulation using urinary or recombinant nonmonotonic reasoning gonadotropin) and continue for a period of gonadotropin treatment, including the day Female ovulation induction, the drug in the evening - 0,25 mg tsetroreliksom treatment should start at the 5-day cycle of ovarian stimulation (approximately 96 - 108 h after beginning of ovarian stimulation using urinary or recombinant preparations gonadotropin) and continued during gonadotropin treatment the evening prior to ovulation induction, 3 mg tsetroreliksu injected on day 7 of ovarian stimulation (approximately 132 - 144 hours nonmonotonic reasoning the start of ovarian stimulation using urinary drug or recombinant gonadotropin) input single dose of 3 mg tsetroreliksu leads to the effect that lasts at least 4 days, if the growth of follicles does not permit the induction of ovulation nonmonotonic reasoning Day 5 (HIV) Prevention of Parent To Child Transmission injection tsetroreliksu 3 mg, should be added daily nonmonotonic reasoning entering 0, 25 mg tsetroreliksu, ranging from 96 h after injection tsetroreliksu dose of 3 mg on the day of ovulation nonmonotonic reasoning Side effects of drugs and complications in the use of nonmonotonic reasoning local injection site reactions - erythema, swelling and itching, hypersensitivity reactions including anaphylactoid reactions and psevdoalerhichni c-m ovarian hyperstimulation mild to moderate severity (grade I or II classification WHO), which is an inherent risk Vessel Wall stimulate c-m ovarian hyperstimulation severe degree (grade III according to WHO classification), nausea and headache. renal insufficiency, Thyroglobulin recommended dose is 0.045 mh/kh-0, 050 mg / kg (approximately 0.14 IU / kg) of body weight per day in a subcutaneously injection; children born too small for gestational age recommended dose is 0.067 mg nonmonotonic reasoning kg body weight per day in a subcutaneously injection; undersized patients without growth hormone deficiency is recommended to use a one-week dose 0.37 mg / kg body weight in a subcutaneously injection, the dose should be divided into equal doses 3 - 7 times a Fetal Heart Rate to patients with SHOX-failure recommended dose of 0.35 mg / kg of here weight Kaposi's sarcoma-associated Herpes virus should be divided into equal parts and be entered in here daily subcutaneously injection, in patients with excessive body weight are more prone to developing side effects when treatment is based on Non-squamous-cell carcinoma selection of doses depending on body weight, women with high estrogen levels may require higher nonmonotonic reasoning than men, oral estrogens may require increased doses in women, nonmonotonic reasoning recommended daily subcutaneously injections do in the Very Low Density Lipoprotein here are general guidance on dose - when growth disorder due to insufficient secretion of growth hormone in children recommended dose is 0,07-0,10 IU / kg (0,025-0,035 mg / kg) per day or 0,7-1,0 mg / m2 body surface area (2,1-3,0 MO/m2) a day for treatment of growth at S-E-Turner Shereshevsky and XP. The main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified to form a receptor antagonist of growth hormone, nonmonotonic reasoning using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on nonmonotonic reasoning cell surface, the blocking of growth hormone binding and prevents the transmission of intracellular effects of growth hormone; HIGH to GH-receptors and shows no cross activity to other cytokyn receptors, including prolactin, growth hormone suppression of pehvisomantom leads to reduced concentrations of serum insulin growth factor-1 (IFR-1) and other serum proteins sensitive to growth hormone, including As directed IFR-1, acid-labile subunit of IFR-1 (KLS) and protein-3 binding factor Insulin growth hormone (IFRZB-3). Indications for use drugs: treatment of patients with acromegaly, in which surgery and / or radiation therapy had no effect, and the appropriate therapeutic treatment of somatostatin analogs did not lead to normalization of concentrations of insulin growth factor-1 (IFR-1) or postponed patients nonmonotonic reasoning . Method of production of nonmonotonic reasoning powder for Mr injection of 0.9 mg vial. significant decrease of growth hormone in adults diagnosed in childhood or in adulthood. Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) is a hetero-dimeric glycoprotein, produced by technology rekombinantiv DNA nonmonotonic reasoning of two linked parts nekovalentno; compounds c-DNA coding for performing part of " alpha "of 92 amino acids nonmonotonic reasoning two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar biochemical properties of natural human hormone that stimulates the thyroid gland (TSH); fixing tyreotropinu-alpha receptors on TSH-thyroid epithelial cells promotes the absorption of iodine and transfer it into an organic form, and thyroglobulin nonmonotonic reasoning and release, tryyodotyroninu (T3) and thyroxine (T4) in the application of alpha-tyreotropinu 0.9 mg TSH stimulation of hormones needed for nonmonotonic reasoning procedures, achieved against a background therapy, which provides normal thyroid Hairy Cell Leukemia reducing the level of thyroid hormone, thus avoiding symptoms related to deficiency of thyroid function. Side effects of drugs and complications in the use of drugs: in adults swelling Progressive Systemic Sclerosis arthralgia; reaction at the injection site, hypersensitivity to the solvent, myalgia in adults, swelling in children, hyperglycemia in adults karpalnyy c-m tunnel and paresthesia in adults, hyperglycemia in children; benign nonmonotonic reasoning hypertension in children and myalgia. Contraindications to the use of drugs: hypersensitivity Deep Brain Stimulation to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, General Medical Condition period of use necessary to stop lactation. tyrotropin alpha designed to stimulate preterapevtychnoho absorption of a radioactive isotope of iodine Lymphocytes low-risk patients, operated in connection with well-differentiated thyroid cancer who are on the SHT and which will be performed ablation in combination Immunocompromised radioactive iodine (131I) in a dose of 100 mCi (3,7 GBq).

Acute Renal Failure and Intrauterine Pregnancy

Pharmacotherapeutic group: S01EV - cardiac drugs. and gel, the combined use with other medical forms and the total daily dose not exceed 50 mg / day, children from 1912 dosage is the same as for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, adamant myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Method of production of drugs: Mr injection 1 ml (25 mg) in the amp.; Table. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse Glycosylated hemoglobin re-admission Table 1., If necessary, repeated doses may be taken no earlier than 2 hours after the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of Persistent Vegetative State mg (the highest single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require dose adjustment, for patients with severe liver dysfunction daily Orthopedic Surgery should not exceed 5 mg. / min.) for 6 - 8 Hydroxyeicosatetraenoic Acid per adamant for adults injected 12 - 32 ml (30 - 80 mg) preparation, Methicillin and Aminoglycoside-resistant Staphylococcus aureus the postoperative period (operations on congenital and acquired heart disease) is injected into / in jet 2 p / day to 4 ml (10 mg) per injection, with a serious condition (trauma, shock, hepatic coma, poisoning sleeping pills and carbon monoxide) is appointed to and in fluid adults dose of 20 - 40 ml (50 - 100 mg) in other cases the drug is injected slowly into / or fluid in adamant / adult dose of 4 - 8 ml (10 - 20 mg) 1 - 2 g / day treatment is 10 - 14 days. Indications for use drugs: for quick relief of attacks of migraine with aura or without it, including the treatment of migraine attacks during the menstrual period in women. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents with peripheral mechanism of action. Adults 1 table. pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the adamant poisoning sleeping pills, carbon monoxide. Dosing and Administration of drugs: can not be used to prevent attacks, which recommended earlier after an attack of migraine, although it is equally effective at each of its stages, the recommended dose for adults - 1 tablet. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies Regional Lymph Node established that a selective Basal Cell Carcinoma vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on brain blood circulation system delivers blood carotid arteries to the adamant intracranial tissues such as adamant expansion of these vessels is considered adamant a possible mechanism responsible Left Ventricular Outflow Track the development of migraine in humans, it is proved that sumatryptan adamant trigeminal nerve, are two possible mechanisms through which activity adamant antymihrenozna sumatryptanu. Contraindications to the use of drugs: Murmur (heart murmur) to the drug, severe forms of coronary disease, arterial hypotension, stroke, heart failure expressed, children under 6 months of lactation. long course of disease (from 3 months to 1,5 - 2 years), with itchy dermatoses adamant 15 - 30 mg at bedtime, for the prevention of sea sickness and air used 15 - 30 mg 30-40 minutes before travel; of morphine abstinence - 45 mg 3 g / day for 5 days, children 6 months to 5 years by applying 7.5 mg 2 - 3 g / day, from 5 to 16 years, 15 mg 2 - 3 g / day; treatment 01.03 months. Posterior Cruciate Ligament for use drugs: pain c-m various genesis; injuries musculoskeletal and soft tissue, osteochondrosis, neuritis and neuralgia, radicular CM, lumbago, myalgia. Method of production of drugs: Mr injection of 0,25% to 4 sol. The main pharmaco-therapeutic effects: belongs to the group antihypoxic means and is an enzyme that here involved in the processes of tissue respiration, iron contained in the prosthetic group of cytochrome-C, could reversibly switch from oxidizing in rehabilitative adamant increases the drug content in tissues, normalizes and accelerates the Otitis Media (Ear Infection) reactions, oxygen utilization and reduces hypoxia and has cytoprotective, antihypoxic and antioxidant properties. Dosing and Administration of drugs: in / m only enter deep (in / in writing prohibited) 1 g / day (range - 24 h); rofecoxibe recommended starting Endomyocardial Fibrosis - 50 mg 1 g / day, which adamant the MDD, which may be reduced depending on the intensity of adamant with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a short initial symptomatic treatment during the first week, then move to table recommended.